Toronto Dominion Bank lifted its position in CVS Health Co. (NYSE:CVS - Free Report) by 124.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,508,071 shares of the pharmacy operator's stock after purchasing an additional 836,569 shares during the quarter. Toronto Dominion Bank owned about 0.12% of CVS Health worth $94,828,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. lifted its holdings in shares of CVS Health by 9.7% during the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator's stock worth $25,781,000 after acquiring an additional 36,132 shares during the last quarter. Cullinan Associates Inc. lifted its position in CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator's stock worth $7,125,000 after buying an additional 37,395 shares during the last quarter. Sompo Asset Management Co. Ltd. grew its position in CVS Health by 8.4% during the third quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock valued at $8,459,000 after acquiring an additional 10,453 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of CVS Health in the 2nd quarter worth approximately $57,584,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of CVS Health by 5.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 448,323 shares of the pharmacy operator's stock valued at $28,191,000 after purchasing an additional 24,285 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS has been the subject of several analyst reports. Barclays dropped their target price on CVS Health from $75.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday, November 7th. Evercore ISI increased their price objective on CVS Health from $62.00 to $75.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. UBS Group upped their target price on CVS Health from $60.00 to $62.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Mizuho cut their price target on shares of CVS Health from $73.00 to $66.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Royal Bank of Canada dropped their target price on shares of CVS Health from $68.00 to $58.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $70.50.
Get Our Latest Analysis on CVS
Shares of NYSE:CVS opened at $55.15 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The business has a 50 day simple moving average of $59.21 and a two-hundred day simple moving average of $58.78. CVS Health Co. has a 1 year low of $52.71 and a 1 year high of $83.25. The firm has a market capitalization of $69.40 billion, a PE ratio of 14.00, a price-to-earnings-growth ratio of 0.95 and a beta of 0.54.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.08 by $0.01. The company had revenue of $95.43 billion for the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. CVS Health's quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.21 EPS. On average, equities analysts predict that CVS Health Co. will post 5.32 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.82%. The ex-dividend date of this dividend was Monday, October 21st. CVS Health's dividend payout ratio (DPR) is presently 67.51%.
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.